Entered a Securities Purchase Agreement on March 27, 2026 for a private placement of 26,713,636 common shares at $4.15 and 9,430,959 pre‑funded warrants at $4.1499 per underlying share, for expected gross proceeds of approximately $150.0 million. Pre‑funded warrants are immediately exercisable at $0.0001 per share and do not expire until fully exercised; beneficial ownership is capped at 4.99% or 9.99% (adjustable up to 19.99% with 61 days’ notice). Closing is expected on March 31, 2026, subject to customary conditions; Leerink Partners is lead placement agent with Evercore, LifeSci Capital, and Oppenheimer as co‑agents. Use of proceeds: fund preclinical and clinical development of next‑generation PI3K pan‑mutant‑selective inhibitor candidates (OKI‑345 in breast cancer; OKI‑355 in vascular anomalies) and for working capital/general corporate purposes. Registration Rights Agreement: Company to file a resale registration statement within 30 days of closing and use reasonable best efforts to have it effective no later than the earlier of 90 days after the agreement date, 120 days after initial filing if reviewed, or the 5th business day after ‘no review’ notice; liquidated damages of 1.0% per 30 days (capped at 5%) if deadlines are missed, subject to carve‑outs. Lock‑ups: executive officers and directors agreed to a lock‑up until the later of 180 days post‑closing and the registration statement’s effective date; the Company agreed to issuance and other restrictions over the same period without lead investor consent. Governance: Lead investor (AI Biotechnology LLC) receives the right to designate one director while it owns ≥50% of purchased securities; the board elected Dr. Liam Ratcliffe as a Class I director, effective upon closing. Program update: Planning IND submissions for OKI‑345 and OKI‑355 in H1 2027; will not further pursue independent development of OKI‑219 at this time; PIKture‑01 trial enrollment completed for monotherapy (n=38) and OKI‑219+fulvestrant (n=33); Phase 2 dose selection for two triplets to complete in 2026; mature data intended by year‑end 2026.